Association of Early-Onset Spasticity and Risk for Cognitive Impairment With Mutations at Amino Acid 499 in SPAST

Abstract

Hereditary spastic paraplegia is a phenotypically and genetically heterogeneous group of neurodegenerative disorders characterized by lower extremity weakness and spasticity. Spastic paraplegia 4 (SPG4), caused by heterozygous mutations in the gene SPAST, typically causes a late-onset, uncomplicated form of hereditary spastic paraplegia in affected individuals. Additional clinical features in SPG4 have been reported on occasion, but no genotype-phenotype correlation has been established. Through targeted clinical testing, we identified 2 unrelated female patients with the same de novo p.Arg499His mutation in SPAST. Both patients presented with early-onset spasticity resulting in delayed motor milestones, which led to a diagnosis of cerebral palsy in one child and tethered cord in the other. Review of the literature identified several patients with mutations at amino acid 499 and early-onset symptoms associated with a risk of cognitive impairment. Early and accurate diagnosis of children with early-onset spasticity is important for informed prognosis and genetic counselling.

Keywords

SPAST early-onset spasticity cognitive impairment cerebral palsy next-generation sequencing

Get full access to this article

View all access options for this article.

References

Harding

. Classification of the hereditary ataxias and paraplegias. Lancet. 1983;1(8334):1151–1155.

Fink

. Hereditary spastic paraplegia: clinical principles and genetic advances. Semin Neurol. 2014;34(3):293–305.

Hazan

Fonknechten

Mavel

. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet. 1999;23(3):296–303.

Errico

Ballabio

Rugarli

. Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics. Hum Mol Genet. 2002;11(2):153–163.

Stenson

Ball

Mort

. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat. 2003;21:577–581.

Shoukier

Neesen

Sauter

. Expansion of mutation spectrum, determination of mutation cluster regions and predictive structural classification of SPAST mutations in hereditary spastic paraplegia. Eur J Hum Genet. 2009;17(2):187–194.

Chrestian

Dupre

Gan-Or

. Clinical and genetic study of hereditary spastic paraplegia in Canada. Neurol Genet. 2016;3(1): e122.

Fonknechten

Mavel

Byrne

. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet. 2000;9(4):637–644.

Magariello

Muglia

Patitucci

. Mutation analysis of the SPG4 gene in Italian patients with pure and complicated forms of spastic paraplegia. J Neurol Sci. 2010;288(1-2):96–100.

10.

Alber

Pernauer

Schwan

. Spastin related hereditary spastic paraplegia with dysplastic corpus callosum. J Neurol Sci. 2005;236(1-2):9–12.

11.

Ribai

Depienne

Fedirko

. Mental deficiency in three families with SPG4 spastic paraplegia. Eur J Hum Genet. 2008;16(1):97–104.

12.

Park

Kim

. Mutation analysis of SPG4 and SPG3A genes and its implication in molecular diagnosis of Korean patients with hereditary spastic paraplegia. Arch Neurol. 2005;62(7):1118–1121.

13.

Polymeris

Tessa

Anagnostopoulou

. A series of Greek children with pure hereditary spastic paraplegia: clinical features and genetic findings. J Neurol. 2016;263(8):1604–1611.

14.

Depienne

Tallaksen

Lephay

. Spastin mutations are frequent in sporadic spastic paraparesis and their spectrum is different from that observed in familial cases. J Med Genet. 2006;43(3):259–265.

15.

Svenson

Kloos

Gaskell

. Intragenic modifiers of hereditary spastic paraplegia due to spastin gene mutations. Neurogenetics. 2004;5(3):157–164.